In 2016, Oncolix, Inc. closed the transaction. The company has received $50,000 in its second tranche. The company received $200,000 in funding so far in the transaction. The company issued 10% secured note and a warrant to acquire 133,335 shares of series A preferred stock at a price of $1.65 per share till January 2022. The notes have maturities between March 2017 and May 2017 and are secured by the assets of the company.